GSK Secures US FDA Breakthrough Therapy Designation For B7-H3-Targeted Antibody-Drug Conjugate In Relapsed Or Refractory Extensive-Stage Small-Cell Lung Cancer
Portfolio Pulse from Benzinga Newsdesk
GSK has received the US FDA Breakthrough Therapy Designation for its B7-H3-targeted antibody-drug conjugate, aimed at treating relapsed or refractory extensive-stage small-cell lung cancer. This designation could expedite the development and review process of the drug.
August 27, 2024 | 6:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GSK has received a significant regulatory boost with the FDA's Breakthrough Therapy Designation for its new cancer treatment, potentially accelerating its path to market.
The FDA Breakthrough Therapy Designation is a significant regulatory milestone that can expedite the development and review of a drug. This is likely to positively impact GSK's stock as it suggests potential for faster market entry and revenue generation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100